How MSI and TMB Factor into Current Biomarker Testing PanelsVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.
Dixie-Lee Esseltine, MD and George Mulligan, PhD shed light on the challenges that payers and practice managers will face as more oncolytics come into the market.